Brokerages Expect Exelixis, Inc. (EXEL) Will Post Quarterly Sales of $118.16 Million
Brokerages expect Exelixis, Inc. (NASDAQ:EXEL) to report $118.16 million in sales for the current fiscal quarter, Zacks reports. Six analysts have made estimates for Exelixis’ earnings, with estimates ranging from $108.10 million to $133.73 million. Exelixis posted sales of $77.58 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 52.3%. The business is expected to announce its next earnings results on Monday, February 26th.
According to Zacks, analysts expect that Exelixis will report full year sales of $118.16 million for the current fiscal year, with estimates ranging from $440.40 million to $466.03 million. For the next year, analysts forecast that the firm will report sales of $627.56 million per share, with estimates ranging from $515.80 million to $762.02 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Exelixis.
Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported $0.26 EPS for the quarter, beating the Zacks’ consensus estimate of $0.08 by $0.18. The business had revenue of $152.50 million during the quarter, compared to analyst estimates of $104.91 million. Exelixis had a net margin of 36.80% and a return on equity of 105.47%. Exelixis’s quarterly revenue was up 145.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.04) EPS.
Shares of Exelixis (NASDAQ:EXEL) traded down $0.44 during mid-day trading on Wednesday, reaching $30.22. 3,018,282 shares of the company’s stock were exchanged, compared to its average volume of 2,940,000. The company has a market cap of $8,810.00, a price-to-earnings ratio of 61.67, a PEG ratio of 0.86 and a beta of 1.84. Exelixis has a fifty-two week low of $18.03 and a fifty-two week high of $32.50.
In other news, Director Alan M. Garber sold 15,000 shares of the company’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $30.30, for a total value of $454,500.00. Following the completion of the sale, the director now owns 64,829 shares in the company, valued at approximately $1,964,318.70. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 5.10% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Matrix Capital Management Company LP grew its position in Exelixis by 8.8% during the second quarter. Matrix Capital Management Company LP now owns 15,117,460 shares of the biotechnology company’s stock valued at $372,343,000 after buying an additional 1,225,000 shares during the period. Jennison Associates LLC grew its position in Exelixis by 38.1% during the fourth quarter. Jennison Associates LLC now owns 4,228,761 shares of the biotechnology company’s stock valued at $128,554,000 after buying an additional 1,167,758 shares during the period. Wells Fargo & Company MN grew its position in Exelixis by 36.5% during the third quarter. Wells Fargo & Company MN now owns 3,042,694 shares of the biotechnology company’s stock valued at $73,723,000 after buying an additional 814,177 shares during the period. American Century Companies Inc. grew its position in Exelixis by 426.4% during the fourth quarter. American Century Companies Inc. now owns 1,469,945 shares of the biotechnology company’s stock valued at $44,686,000 after buying an additional 1,190,691 shares during the period. Finally, Pictet Asset Management Ltd. grew its position in Exelixis by 18.7% during the third quarter. Pictet Asset Management Ltd. now owns 1,317,631 shares of the biotechnology company’s stock valued at $31,926,000 after buying an additional 207,868 shares during the period. Institutional investors own 80.60% of the company’s stock.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.